Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DSP107 |
Trade Name | |
Synonyms | DSP-107|DSP 107|SIRPa-4-1BBL DSP107|SIRPa 4-1BBL DSP107 |
Drug Descriptions |
DSP107 is a bi-functional trimeric fusion protein that consists of extracellular domains of SIRP alpha and 4-1BBL, which blocks the interaction between CD47 and SIRP alpha, and simultaneously activates the co-stimulatory receptor 4-1BB, potentially activating innate and adaptive immune responses, and inducing cytotoxicity and phagocytosis of tumor cells (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A076; Blood (2020) 136 (Supplement 1): 19-20). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C174171 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + DSP107 | Atezolizumab DSP107 | 0 | 1 |
Azacitidine + DSP107 + Venetoclax | Azacitidine DSP107 Venetoclax | 0 | 1 |
Cetuximab + DSP107 | Cetuximab DSP107 | 0 | 0 |
DSP107 | DSP107 | 0 | 1 |
DSP107 + Rituximab | DSP107 Rituximab | 0 | 0 |